27.07.2011 • News

Pharmaceutical Product Development Q2 Profit Rises

 

Pharmaceutical Product Development reported second-quarter net income attributable to shareholders of $46.51 million or $0.41 per share, compared to $20.98 million or $0.18 per share in the prior-year period.

On average, 12 analysts polled by Thomson Reuters expected earnings of $0.38 per share for the quarter. Analysts' estimate typically excludes one-time items.

Net revenue for the quarter grew 10.2% to $407.70 million from $369.92 million in the second quarter of last year, while11 analysts estimated revenues of $370.79 million for the quarter.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read